Cullinan Therapeutics publishes positive preliminary data from Zipalertinib's critical phase 2B Rezilient1 study
Cullinan Therapeutics公布了Zipalertinib的关键性2B期Rezilient1研究的积极初步数据
Cullinan Therapeutics publishes positive preliminary data from Zipalertinib's critical phase 2B Rezilient1 study
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.